Special Issue "Transdermal Delivery Systems: Current Landscape and Trends"
Deadline for manuscript submissions: closed (15 September 2016)
Prof. Dr. Yogeshvar N. Kalia
School of Pharmaceutical Sciences, University of Geneva & University of Lausanne, Geneva, Switzerland
Website | E-Mail
Interests: transdermal delivery; ocular delivery; buccal delivery; biological models for intestinal absorption; prodrugs; micelles; nanocarriers; iontophoresis; fractional laser ablation; bioequivalence; biodistribution
The perceived limitations of: (i) topical drug delivery to the skin for the targeted local treatment of disease; and (ii) transdermal drug delivery for systemic therapy, are being challenged by the development of new formulation strategies and delivery technologies. There is also an increased perception of the need to provide more targeted therapy and thereby to improve efficacy and to decrease the risk of side-effects: "the right drug, at the right place, at the right time". These drivers have led to considerable innovation, interest and progress in the field. Although, there is a general assumption as to the "optimal" physicochemical properties of a drug candidate for delivery into the skin, theory and practice can be very different. For example, locally acting therapeutics used to target dermatological diseases include aciclovir (log P −1.5) and adapalene (log P 8.2), an almost ten log unit difference in lipophilicity. The efficient, targeted delivery of such disparate molecules should require very different strategies. Peptides and proteins, including antibodies, have also been delivered into and across the skin using new technologies—these biomolecules are obviously very different from low molecular weight, lipophilic therapeutics which are the "conventional" candidates for transdermal delivery. The aim of this Special Issue is to provide a platform to present the latest developments in drug delivery and vaccination—in short, to show how the "impossible" is becoming possible.
Prof. Dr. Yogeshvar Kalia
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- transdermal delivery
- topical delivery
- drug delivery
- follicular delivery
- chemical penetration enhancers
- laser ablation
- topical delivery